Material Event (Form 8-K)

Item 8.01 Other Information.

As previously reported on Current Report on From 8-K filed on February 14, 2025 (the "February 8-K"), on February 14, 2025, pursuant to a prospectus supplement to a previously filed shelf registration statement on Form S-3 (File No. 333-262554) of Vivos Therapeutics, Inc., (the "Company"), the Company entered into an At The Market Offering Agreement (the "ATM Sales Agreement") with H.C. Wainwright & Co., LLC, as agent ("Wainwright"), pursuant to which the Company may offer and sell, from time to time through Wainwright shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). As of the date hereof, the Company has not sold any shares of Common Stock pursuant to the ATM Sales Agreement.

On September 12, 2025, the Company filed a prospectus supplement (the "ATM Pro Supp") Securities and Exchange Commission (the "SEC") pursuant to which the Company may continue, under the ATM Sales Agreement, to sell, from time to time, up to an aggregate sales price of $5,830,572 of its Common Stock (the "Shares"), through Wainwright as sales agent.

The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-284834), as amended, initially filed by the Company with the SEC on February 11, 2025 and declared effective by the SEC on September 10, 2025, as supplemented by the ATM Pro Supp filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act").

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

A copy of the opinion of Ellenoff Grossman & Schole LLP relating to the legality of the Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K and incorporated by reference herein. Please refer to the February 8-K for the full text of the ATM Sales Agreement.